Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Racephedrine is the racemic form of ephedrine—a sympathomimetic amine and bronchodilator. It consists of equal parts of the two enantiomers of ephedrine ((1R,2S) and (1S,2R)). Racephedrine has been used as a bronchodilator to treat asthma and other conditions involving bronchospasm. Its mechanism involves acting as a norepinephrine releasing agent and weak dopamine releasing agent; both enantiomers are active but the natural l-ephedrine is more potent. Like other sympathomimetics in its class it stimulates adrenergic receptors directly and indirectly by increasing synaptic norepinephrine levels[5][6]. Racephedrine has been marketed for medical use in Italy under brand names such as Efetonina and Ephoxamine[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on racephedrine.